Cubist Systematic Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $616K | Buy |
+1,352
| New | +$551K | ﹤0.01% | 2181 |
|
|
2024
Q2 | – | Sell |
-90,234
| Closed | -$14.2M | – | 2914 |
|
|
2024
Q1 | $13.5M | Buy |
90,234
+72,220
| +401% | +$12M | 0.08% | 346 |
|
|
2023
Q4 | $3.45M | Buy |
18,014
+2,333
| +15% | +$397K | 0.02% | 1102 |
|
|
2023
Q3 | $2.78M | Buy |
15,681
+11,212
| +251% | +$2.14M | 0.02% | 1132 |
|
|
2023
Q2 | $849K | Buy |
4,469
+3,411
| +322% | +$676K | 0.01% | 2063 |
|
|
2023
Q1 | $212K | Sell |
1,058
-12,414
| -92% | -$2.61M | ﹤0.01% | 3199 |
|
|
2022
Q4 | $3.2M | Sell |
13,472
-89,342
| -87% | -$19.1M | 0.02% | 1423 |
|
|
2022
Q3 | $20.6M | Buy |
102,814
+96,603
| +1,555% | +$18.4M | 0.12% | 146 |
|
|
2022
Q2 | $906K | Sell |
6,211
-21,989
| -78% | -$3.12M | 0.01% | 2560 |
|
|
2022
Q1 | $4.61M | Buy |
28,200
+10,534
| +60% | +$1.6M | 0.04% | 794 |
|
|
2021
Q4 | $3M | Buy |
17,666
+778
| +5% | +$145K | 0.03% | 1023 |
|
|
2021
Q3 | $3.19M | Sell |
16,888
-5,481
| -25% | -$1.03M | 0.04% | 721 |
|
|
2021
Q2 | $3.79M | Buy |
22,369
+21,318
| +2,028% | +$3.12M | 0.04% | 712 |
|
|
2021
Q1 | $148K | Sell |
1,051
-22,191
| -95% | -$3.34M | ﹤0.01% | 2563 |
|
|
2020
Q4 | $3.02M | Buy |
23,242
+10,553
| +83% | +$1.41M | 0.04% | 707 |
|
|
2020
Q3 | $1.85M | Sell |
12,689
-5,733
| -31% | -$815K | 0.03% | 956 |
|
|
2020
Q2 | $2.73M | Buy |
+18,422
| New | +$2.48M | 0.05% | 621 |
|
|
2020
Q1 | – | Sell |
-65,713
| Closed | -$7.57M | – | 2140 |
|
|
2019
Q4 | $7.57M | Buy |
65,713
+64,970
| +8,744% | +$6.48M | 0.14% | 163 |
|
|
2019
Q3 | $60K | Sell |
743
-27,152
| -97% | -$2.15M | ﹤0.01% | 2012 |
|
|
2019
Q2 | $2.02M | Buy |
+27,895
| New | +$2.14M | 0.04% | 684 |
|
|
2019
Q1 | – | Sell |
-30,178
| Closed | -$2.2M | – | 2223 |
|
|
2018
Q4 | $2.2M | Buy |
30,178
+20,227
| +203% | +$1.56M | 0.1% | 242 |
|
|
2018
Q3 | $871K | Buy |
9,951
+9,760
| +5,110% | +$982K | 0.05% | 528 |
|
|
2018
Q2 | $19K | Sell |
191
-2,735
| -93% | -$271K | ﹤0.01% | 1704 |
|
|
2018
Q1 | $348K | Sell |
2,926
-15,684
| -84% | -$2.02M | 0.02% | 1048 |
|
|
2017
Q4 | $2.36M | Buy |
18,610
+17,818
| +2,250% | +$2.24M | 0.13% | 175 |
|
|
2017
Q3 | $93K | Sell |
792
-1,906
| -71% | -$163K | 0.01% | 1643 |
|
|
2017
Q2 | $215K | Sell |
2,698
-6,397
| -70% | -$409K | 0.01% | 1243 |
|
|
2017
Q1 | $466K | Buy |
9,095
+1,457
| +19% | +$67.3K | 0.03% | 675 |
|
|
2016
Q4 | $286K | Sell |
7,638
-4,230
| -36% | -$177K | 0.02% | 985 |
|
|
2016
Q3 | $804K | Buy |
11,868
+8,376
| +240% | +$591K | 0.05% | 500 |
|
|
2016
Q2 | $194K | Sell |
3,492
-8,663
| -71% | -$546K | 0.01% | 1350 |
|
|
2016
Q1 | $763K | Buy |
12,155
+7,748
| +176% | +$515K | 0.04% | 572 |
|
|
2015
Q4 | $415K | Sell |
4,407
-15,676
| -78% | -$1.45M | 0.02% | 922 |
|
|
2015
Q3 | $1.61M | Buy |
20,083
+5,653
| +39% | +$628K | 0.08% | 351 |
|
|
2015
Q2 | $1.73M | Buy |
14,430
+13,840
| +2,346% | +$1.65M | 0.08% | 321 |
|
|
2015
Q1 | $62K | Buy |
590
+578
| +4,817% | +$58.6K | ﹤0.01% | 1728 |
|
|
2014
Q4 | $1K | Buy |
+12
| New | +$1.11K | ﹤0.01% | 1849 |
|
|
2014
Q3 | – | Sell |
-57,864
| Closed | -$3.65M | – | 1727 |
|
|
2014
Q2 | $3.65M | Buy |
+57,864
| New | +$3.44M | 0.22% | 94 |
|
Other funds holding ALNY
Cubist Systematic Strategies's ALNY Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 1,352 shares worth $616K. The stake represents ﹤0.01% of the portfolio and ranks #2181 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ALNY as recently as Q1 2024.
Cubist Systematic Strategies first reported a position in ALNY in Q2 2014 and has held it in 38 quarters since. The position peaked at $20.6M in Q3 2022. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.
- Cubist Systematic Strategies held 1,352 shares of Alnylam Pharmaceuticals worth $616K as of Q3 2025.
- Alnylam Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
- Alnylam Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2181 holding.
- Cubist Systematic Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
- Cubist Systematic Strategies's Alnylam Pharmaceuticals position peaked at $20.6M in Q3 2022.
- 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.